First-line Treatment in Parkinson’s Disease
Identifieur interne : 001494 ( Main/Exploration ); précédent : 001493; suivant : 001495First-line Treatment in Parkinson’s Disease
Auteurs : C. A. Davie ; A. H. V. Schapira [Royaume-Uni]Source :
- Practical Neurology [ 1474-7758 ] ; 2005-06.
Abstract
Parkinson’s disease is a common neurodegenerative condition with a prevalence of about 160/100 000 in Western Europe rising to as high as 2% of the population over 80 years old (Mutch et al. 1986). The disease has a major socio-economic impact. The annual direct cost of care per patient is about £6000, while the indirect costs and the burden of the disease on patients and their carers are incalculable (Findley et al. 2003). Furthermore, a move from home to residential care is associated with an approximately 500% cost increase. Therefore, the management of Parkinson’s disease is likely to prove an increasingly important and challenging aspect of medical practice as the population ages. Therapeutic strategies have for the large part focused on pharmacological agents, and there has also been an increasing trend towards specialist Parkinson’s disease clinics run by physicians with a specific interest in the disease. Such clinics often provide
Url:
DOI: 10.1111/j.1474-7766.2005.00303.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">First-line Treatment in Parkinson’s Disease</title><author><name sortKey="Davie, C A" sort="Davie, C A" uniqKey="Davie C" first="C. A." last="Davie">C. A. Davie</name></author><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AA0E90B8E3CA45120E404D2BC8486E4F1D0D06C9</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1111/j.1474-7766.2005.00303.x</idno><idno type="url">https://api.istex.fr/document/AA0E90B8E3CA45120E404D2BC8486E4F1D0D06C9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000740</idno><idno type="wicri:Area/Main/Curation">000648</idno><idno type="wicri:Area/Main/Exploration">001494</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">First-line Treatment in Parkinson’s Disease</title><author><name sortKey="Davie, C A" sort="Davie, C A" uniqKey="Davie C" first="C. A." last="Davie">C. A. Davie</name><affiliation><wicri:noCountry code="subField">Royal Free and University College Medical School and</wicri:noCountry></affiliation></author><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, and Institute of Neurology, Queen Square, University College London</wicri:regionArea><wicri:noRegion>University College London</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Practical Neurology</title><title level="j" type="abbrev">Pract Neurol</title><idno type="ISSN">1474-7758</idno><idno type="eISSN">1474-7766</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2005-06">2005-06</date><biblScope unit="volume">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="160">160</biblScope></imprint><idno type="ISSN">1474-7758</idno></series><idno type="istex">AA0E90B8E3CA45120E404D2BC8486E4F1D0D06C9</idno><idno type="DOI">10.1111/j.1474-7766.2005.00303.x</idno><idno type="href">practneurol-5-160.pdf</idno><idno type="local">pnr_303</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-7758</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson’s disease is a common neurodegenerative condition with a prevalence of about 160/100 000 in Western Europe rising to as high as 2% of the population over 80 years old (Mutch et al. 1986). The disease has a major socio-economic impact. The annual direct cost of care per patient is about £6000, while the indirect costs and the burden of the disease on patients and their carers are incalculable (Findley et al. 2003). Furthermore, a move from home to residential care is associated with an approximately 500% cost increase. Therefore, the management of Parkinson’s disease is likely to prove an increasingly important and challenging aspect of medical practice as the population ages. Therapeutic strategies have for the large part focused on pharmacological agents, and there has also been an increasing trend towards specialist Parkinson’s disease clinics run by physicians with a specific interest in the disease. Such clinics often provide</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Davie, C A" sort="Davie, C A" uniqKey="Davie C" first="C. A." last="Davie">C. A. Davie</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001494 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001494 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AA0E90B8E3CA45120E404D2BC8486E4F1D0D06C9
|texte= First-line Treatment in Parkinson’s Disease
}}
| This area was generated with Dilib version V0.6.23. |  |